GlassScriptPhysician profile
James G Chelnis
NPI 1952612913
$222,592.99
in general payments reported to CMS, 2019-2025
14 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $2,317 · 2021: $25K · 2022: $59K · 2023: $71K · 2024: $41K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Honoraria: $17K · Consulting Fee: $4,740 · Travel and Lodging: $1,429 · Education: $99.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61,255.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,716.62 |
| Honoraria | $16,943.75 |
| Consulting Fee | $4,740.00 |
| Travel and Lodging | $1,429.24 |
| Education | $99.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $148,577.56 | 2021-2025 | M22, Optilight |
| Horizon Therapeutics Plc | $55,242.26 | 2019-2023 | Tepezza |
| Merz North America, INC. | $5,424.24 | 2019-2025 | Xeomin |
| Lumenis, INC | $5,350.00 | 2020-2021 | |
| Abbvie INC. | $3,180.06 | 2022-2025 | Botox |
| Allergan, INC. | $2,042.00 | 2019-2022 | |
| Amgen INC. | $1,698.66 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $353.66 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $298.18 | 2020-2023 | Acthar |
| Mallinckrodt Enterprises LLC | $124.78 | 2019 | |
| Sun Pharmaceutical Industries INC. | $119.75 | 2022 | |
| Almirall LLC | $105.81 | 2019 | |
| Galderma Laboratories, L.P. | $56.63 | 2022-2024 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chelnis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.